Note 17 - Fair Value Disclosures (Tables)

3 Months Ended

Mar. 31, 2019

Notes Tables

Fair Value, by Balance Sheet Grouping [Table Text Block]

			Fair Value Measured at Reporting Date Using
	Carrying Amount		Level 1		Level 2		Level 3		Fair Value
At March 31, 2019:
Cash and cash equivalents	$	39,752	$	-	$	39,752	$	-	$	39,752
Other receivables	$	417,904	$	-	$	-	$	417,904	$	417,904
Note receivable - related party	$	44,859	$	-	$	-	$	44,859	$	44,859
Advances to CEN Biotech Ukraine, LLC - related party	$	905,328	$	-	$	-	$	905,328	$	905,328
Loans payable	$	10,113,095	$	-	$	-	$	10,113,095	$	10,113,095
Loans payable - related parties	$	1,361,550	$	-	$	-	$	-	$	-
Patent acquisition liability	$	1,010,000	$	-	$	-	$	1,010,000	$	1,010,000
Convertible notes payable	$	5,307,584	$	-	$	-	$	5,768,525	$	5,768,525
Convertible notes payable - related parties	$	2,538,681	$	-	$	-	$	-	$	-

	Carrying Amount		Level 1		Level 2		Level 3		Fair Value
At December 31, 2018:
Cash and cash equivalents	$	3,193	$	-	$	3,193	$	-	$	3,193
Other receivables	$	418,905	$	-	$	-	$	418,905	$	418,905
Note receivable - related party	$	44,859	$	-	$	-	$	44,859	$	44,859
Advances to CEN Biotech Ukraine, LLC - related party	$	875,328	$	-	$	-	$	875,328	$	875,328
Loans payable	$	10,107,205	$	-	$	-	$	10,107,205	$	10,107,205
Loans payable - related parties	$	1,360,806	$	-	$	-	$	-	$	-
Patent acquisition liability	$	1,010,000	$	-	$	-	$	1,010,000	$	1,010,000
Convertible notes payable	$	5,143,647	$	-	$	-	$	5,534,810	$	5,534,810
Convertible notes payable - related parties	$	2,538,681	$	-	$	-	$	-	$	-